Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Vitiligo
Interventions: Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more

Conditions: Healthy Volunteer
Interventions: ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions: Cofetuzumab Pelidotin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more

Conditions: Acute Myeloid Leukemia (AML), Cancer
Interventions: Venetoclax, Azacitidine, Best Supportive Care (BSC); Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Healthy Volunteers
Interventions: nacresertib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Migraine
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atopic Dermatitis
Interventions: Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 63 more

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 74
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more

Conditions: Leukemia
Interventions: Venetoclax, Standard Chemotherapy; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more

Conditions: Migraine
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Hoover, Alabama • Huntsville, Alabama • Phoenix, Arizona + 10 more

Conditions: Healthy Volunteer
Interventions: ABBV-1451, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

About this AbbVie sponsor directory page